Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R30)

Funding Opportunity RFA-FD-17-006 from the NIH Guide for Grants and Contracts. This award is intended to provide support to conduct clinical studies at a clinical site with capability and patients samples to investigate potential biomarker (cMLC1) for trastuzumab-induced cardiotoxicity.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding